Results 21 to 30 of about 20,887 (223)

Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacy [PDF]

Pharmacological Research
Current treatment protocols have limited success against MYCN-amplified neuroblastoma. Adoptive T cell therapy presents an innovative strategy to improve cure rates.
Laura Grunewald, Lena Andersch, Konstantin Helmsauer, Silke Schwiebert, Anika Klaus, Anton G. Henssen, Teresa Straka, Marco Lodrini, Sebastian G. Wicha, Steffen Fuchs, Falk Hertwig, Frank Westermann, Alice Vitali, Carlotta Caramel, Gabriele Büchel, Martin Eilers, Kathy Astrahantseff, Angelika Eggert, Uta E. Höpken, Johannes H. Schulte, Thomas Blankenstein, Kathleen Anders, Annette Künkele   +22 more
doaj   +2 more sources

Integrated Genomic and Proteomic Analysis Reveals T-B Lymphocyte Signatures in the MYCN Driven "Immune Desert" of Specific Neuroblastoma Subtypes. [PDF]

CNS Neurosci Ther
This study identifies a high‐risk neuroblastoma subtype defined by MYCN amplification and an “immune desert” tumor microenvironment. We uncover novel lymphocyte‐specific immunosuppressive networks, including T cell dysfunction and a MYC‐driven B cell hub, revealing potential therapeutic targets.
Hu JJ, Kang WJ, Hu JT, Li YX, Song FJ, Deng M.   +5 more
europepmc   +2 more sources

AOSNP-ADAPTR resource level-based recommendations on practical diagnostic strategies for medulloblastomas and other embryonal tumors. [PDF]

Brain Pathol
Resource level‐based recommendations on practical diagnostic strategies for medulloblastomas and other CNS embryonal tumors are provided. Abstract WHO CNS5 mandates integrated histo‐molecular classification of medulloblastomas (MBs) and other CNS embryonal tumors. However, advanced molecular diagnostics remain inaccessible in many low‐ and lower‐middle‐
Sarkar C, Al-Hussaini M, Santosh V, Suri V, Park SH, Piao YS, Tihan T, Ng HK, Buckland M, Jalali R, Kanemura Y, Wesseling P, Komori T.   +12 more
europepmc   +2 more sources

MYCN and the epigenome [PDF]

Frontiers in Oncology, 2013
It is well known that Neuroblastoma (NB) patients whose tumors have an undifferentiated histology and a transcriptome enriched in cell cycle genes have a worse prognosis. This contrasts with the good prognoses of patients whose tumors have histologic evidence of differentiation and a transcriptome enriched in differentiation genes.
He, Stanley, Liu, Zhihui, Oh, Doo-Yi, Thiele, Carol J.   +3 more
openaire   +3 more sources

Proteogenomic characterization of cholangiocarcinoma

Hepatology, EarlyView., 2022
Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng, Peng Ran, Lingli Chen, Yunzhi Wang, Zixiang Yu, Ke Cai, Jinwen Feng, Zhaoyu Qin, Yanan Yin, Subei Tan, Yang Liu, Chen Xu, Guoming Shi, Yuan Ji, Jian‐Yuan Zhao, Jian Zhou, Jia Fan, Yingyong Hou, Chen Ding   +18 more
wiley   +1 more source

MYCN Function in Neuroblastoma Development [PDF]

Frontiers in Oncology, 2021
Dysregulated expression of the transcription factor MYCN is frequently detected in nervous system tumors such as childhood neuroblastoma. Here, gene amplification ofMYCNis a single oncogenic driver inducing neoplastic transformation in neural crest-derived cells. This abnormalMYCNexpression is one of the strongest predictors of poor prognosis.
Jörg Otte, Cecilia Dyberg, Adena Pepich, John Inge Johnsen   +3 more
openaire   +3 more sources

The MYCN Enigma: Significance of MYCN Expression in Neuroblastoma [PDF]

Cancer Research, 2006
Abstract MYCN amplification strongly predicts adverse outcome of neuroblastoma. However, the significance of MYCN expression in the clinical and biological behavior of neuroblastoma has been unclear. To address this question, we first examined the expression of MYCN in combination with TrkA (a favorable prognostic indicator of ...
Xao X, Tang, Huaqing, Zhao, Bing, Kung, David Y, Kim, Sakeenah L, Hicks, Susan L, Cohn, Nai-Kong, Cheung, Robert C, Seeger, Audrey E, Evans, Naohiko, Ikegaki   +9 more
openaire   +2 more sources

Targeting of the MYCN protein with small molecule c-MYC inhibitors [PDF]

, 2014
This study was funded by grants from the Swedish Research Council and the Swedish Cancer Society. IM and HZ were recipients of graduate student grants from KI (KID), MAH was recipient of a Senior Investigator Award from the Swedish Cancer Society, and ...
Edward V Prochownik, Inga Müller, Oliynyk, G, Ganna Oliynyk (568258), Zirath Hanna, Prochownik Edward V., Larsson, Karin, Anna Frenzel, Marie Arsenian Henriksson, Anna Frenzel (194997), Edward V. Prochownik (163628), Henriksson, MA, Westwood Nicholas J., Oliynyk, Ganna, Hanna Zirath, Marie Arsenian Henriksson (195006), Oliynyk Ganna, Ganna Oliynyk, Larsson, K, Frenzel, A, Frenzel, Anna, Zirath, Hanna, Prochownik, Edward V., Nicholas J Westwood, Frenzel Anna, Zirath, H, Henriksson Marie Arsenian, Karin Larsson, Muller, Inga, Nicholas J. Westwood, Inga Müller (568256), Nicholas J. Westwood (254891), Edward V. Prochownik, Müller, I, Westwood, NJ, Müller Inga, Henriksson, Marie Arsenian, Karin Larsson (568257), Hanna Zirath (195000), Prochownik, EV, Westwood, Nicholas J., Larsson Karin, Oliynyk, G,, Larsson, K,   +43 more
core   +2 more sources

An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability [PDF]

, 2021
To achieve the very high oncoprotein levels required to drive the malignant state cancer cells utilise the ubiquitin proteasome system to upregulate transcription factor levels.
Du, Y, Koach, J, Kanikevich, M, Liu, T ; https://orcid.org/, Parker, MW, Cheung, BB ; https://orcid.org/, Liu, T, Mayoh, C ; https://orcid.org/, Salib, A, Cheung, BB, Seneviratne, JA, Mayoh, C, Nagy, Z, Chang, W, Venkat, P, Marshall, GM, Mittra, R, Jiang, C, Carter, DR   +18 more
core   +1 more source

The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells

BMC Cancer, 2018
Background MYCN is amplified in small cell lung cancers and several pediatric tumors, including alveolar rhabdomyosarcomas and neuroblastomas. MYCN protein is known to play a key oncogenic role in both alveolar rhabdomyosarcomas and neuroblastomas.
Eleanor M. O’Brien, Joanna L. Selfe, Ana Sofia Martins, Zoë S. Walters, Janet M. Shipley   +4 more
doaj   +1 more source